Tetravalent Recombinant Human Papilloma Viruse Vaccines(6,11,16,18)(Hansenula Polymorpha)(Chengdu Institute of Biological Products)

This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial.
This trial plans to enroll 1,800 female subjects aged 9-26 years, 600 in each of the 18-26 years old 3-dose group, 9-17 years old 3-dose group and 9-14 years old 2-dose group.
All subjects in the 9-14 years old 2-dose group will be injected with 2 doses of the experimental vaccine in the deltoid muscle of the upper arm according to the 0-6 month immunization schedule. Subjects in the non-immune persistence subgroup will need to complete 6 on-site visits (V1-V3, V7-V9) and subjects in the immune persistence subgroup will need to complete 12 on-site visits (V1-V3, V7-V15); All subjects in the 9-17 years old 3-dose group and the 18-26 years old 3-dose group will be injected with 3 doses of the experimental vaccine in the deltoid muscle of the upper arm according to the 0, 2, and 6 month immunization schedule. Subjects in the non-immune persistence subgroup will need to complete 9 on-site visits (V1-V9) and subjects in the immune persistence subgroup will need to complete 15 on-site visits (V1-V15).